IOncology

New data from the NATALEE trial reinforce the efficacy of ribociclib in combination with endocrine therapy for HR-positive, HER2-negative early breast cancer. With a median follow-up of 33.3 months, the…

New findings from the KATHERINE trial, published in The New England Journal of Medicine, confirm that trastuzumab emtansine (T-DM1) continues to provide superior survival benefits over trastuzumab alone in HER2-positive…

At the recently held 2024 Precision Medicine Conference on Lung Cancer, Dr. Nan Bi from the Cancer Hospital Chinese Academy of Medical Sciences, delivered a presentation titled "Advances in Radiotherapy for NSCLC in 2024." The talk covered key developments in radiotherapy combined with targeted therapy, radiotherapy combined with immunotherapy, and technological advancements in radiotherapy. In an exclusive interview with Oncology Frontier, Professor Bi further elaborated on some of the most pressing topics in this evolving field.

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. For patients with unresectable HCC, transarterial chemoembolization (TACE) is a standard treatment. The phase 2, multicenter, open-label, randomized CARES-005…

Editor's Note: Refractory cancer pain often responds poorly to standard pain management strategies. Both in vitro and in vivo studies have shown that hawthorn standardized extract (HSE) possesses central and…

At the San Antonio Breast Cancer Symposium 2024, Dr. Paula Ines Gonzalez Ericsson presented important research on HLA class I expression in breast cancer and its implications for immunotherapy response. Her…

At the San Antonio Breast Cancer Symposium 2024, Dr. Charles Geyer, Jr. presented important research focused on improving treatment strategies for triple-negative breast cancer (TNBC). His work continues to drive…

The five-year follow-up data from CheckMate 649, presented at the 2025 ASCO Gastrointestinal Cancers Symposium, confirms the long-term survival benefits of nivolumab plus chemotherapy in advanced gastric, gastroesophageal junction, and…

The phase 3 CheckMate 9DW trial, presented at ASCO24, brings promising results for nivolumab (NIVO) + ipilimumab (IPI) as a potential new standard of care in first-line treatment for unresectable…